News coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive on Sunday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CareDx earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.241881216409 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several equities analysts have weighed in on CDNA shares. Zacks Investment Research upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research report on Monday, September 4th. HC Wainwright started coverage on shares of CareDx in a research report on Monday, November 27th. They set a “buy” rating and a $12.00 price objective on the stock. Craig Hallum reiterated a “buy” rating and set a $10.00 price objective (up from $4.00) on shares of CareDx in a research report on Monday, October 9th. Raymond James Financial upgraded shares of CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Wednesday, September 27th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price objective (up from $3.00) on shares of CareDx in a research report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. CareDx presently has a consensus rating of “Buy” and a consensus target price of $7.75.

CareDx (CDNA) traded down $0.10 during trading on Friday, hitting $7.05. 67,185 shares of the stock traded hands, compared to its average volume of 320,839. The company has a debt-to-equity ratio of -124.53, a quick ratio of 0.35 and a current ratio of 0.55. CareDx has a fifty-two week low of $0.76 and a fifty-two week high of $7.98. The stock has a market cap of $198.84, a PE ratio of -3.90 and a beta of 1.05.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.02. CareDx had a negative net margin of 84.14% and a negative return on equity of 157.00%. The business had revenue of $12.19 million for the quarter, compared to analysts’ expectations of $12.05 million. The firm’s quarterly revenue was down 2.3% on a year-over-year basis. research analysts anticipate that CareDx will post -0.83 earnings per share for the current year.

In related news, major shareholder Neil Gagnon purchased 10,642 shares of the stock in a transaction dated Thursday, October 5th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $42,568.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider James P. Yee sold 29,197 shares of the business’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $7.00, for a total transaction of $204,379.00. Following the transaction, the insider now owns 74,795 shares in the company, valued at $523,565. The disclosure for this sale can be found here. Insiders own 5.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CareDx (CDNA) Receiving Somewhat Favorable News Coverage, Analysis Shows” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Stock Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related stocks with our FREE daily email newsletter.